04th week of 2009 patent applcation highlights part 41 |
Patent application number | Title | Published |
20090023618 | METHOD FOR RECOVERING CRUDE OIL FROM A SUBTERRANEAN FORMATION - An aqueous fluid useful for the recovery of crude oil from a subterranean formation, including water and one or more organophosphorus materials and methods for using same. | 2009-01-22 |
20090023619 | Viscosity modifier of lubricating oil for power transmission system and lubricating oil composition for power transmission system - A lubricating oil composition for a power transmission system, which is excellent in both of low-temperature viscosity property and shear stability, is provided. The viscosity modifier of a lubricating oil for a power transmission system according to the present invention comprises an ethylene/α-olefin copolymer (B) having the properties: (B1) an ethylene content in the range of 70 to 85% by mol, (B2) an intrinsic viscosity [η] in the range of 0.2 to 1.0 dl/g, (B3) Mw/Mn not more than 2.4, and (B4) a melting point, as measured by DSC, not higher than 60° C., or no melting point observed. | 2009-01-22 |
20090023620 | Natural Cleaning Compositions - A cleaning composition with a limited number of natural ingredients contains alkyl polyglucoside, solvent and colloidal silica. The cleaning composition optionally has an additional amount of glycerol. The cleaning composition optionally has a small amount of fragrance. The cleaning composition can be used to clean hard surfaces and cleans as well or better than commercial compositions containing synthetically derived cleaning agents. | 2009-01-22 |
20090023621 | Method for manufacturing a shaped article - A method for manufacturing a shaped article comprising the step of cutting a shaped article from a first article; wherein as the shaped article is cut from the first article the shaped article's cross-section is deformed and wherein the first article's cross-section is shaped such that it compensates for the deformation during the cutting step so as to achieve a shaped article with a desired cross-section. Shaped articles and compositions comprising shaped articles are also described. | 2009-01-22 |
20090023622 | AQUEOUS SURFACE-ACTIVE FORMULATION INCLUDING POLYPROPYLENE GLYCOL(3) MYRISTYL ETHER - The present invention relates to the use of polypropylene glycol(3) myristyl ether as preferably the sole viscosity regulator, care active ingredient and solubilizer in aqueous surface-active formulations, preferably having a water content of at least 75% by weight. The present invention further provides aqueous surface-active formulations comprising at least 0.5% by weight, preferably at least 2% by weight, of polypropylene glycol(3) myristyl ether, at least 5% by weight, preferably at least 10% by weight, of at least one surfactant and at least 75% by weight, preferably at least 85% by weight, of water and liquid body cleansing compositions, in particular shower baths and hair shampoos, comprising such an aqueous surface-active formulation. | 2009-01-22 |
20090023623 | SKIN CLEANSING COMPOSITION - A skin cleansing composition contains, in addition to water, the following ingredients (A) to (D):
| 2009-01-22 |
20090023624 | Detergent compositions - The present invention relates to a detergent composition comprising a new wild-type lipase and variants thereof. In addition a washing method is disclosed. | 2009-01-22 |
20090023625 | Detergent composition containing suds boosting co-surfactant and suds stabilizing surface active polymer - A detergent composition having improved sudsing profile comprising 0.2% to 6% by weight of a suds boosting co-surfactant having the formula R—O—(CH | 2009-01-22 |
20090023626 | Natural fibers wash and rinse and method of using same - A combination of two separate compositions used for cleaning natural fibers and fabrics made therefrom and the method of using same. The first composition provides for low temperature washing of the fibers and contains two different non-ionic surfactants and an anionic surfactant in the ratio of about 3:1 and 1:3 respectively. The composition for the rinse cycle is between about 1 and 3 percent by weight of at least one non-ionic surfactant and between about 15 and 25 percent by weight of a cationic surfactant. | 2009-01-22 |
20090023627 | COMPOSITIONS AND METHODS FOR ALZHEIMER'S DISEASE - The present invention concerns methods and compositions of use for treatment of Alzheimer's Disease (AD). In certain embodiments, the methods concern preparation of phage-display single chain antibody libraries and screening against amyloid-beta (Aβ) protein or peptide. Anti-Aβ antibodies are selected and sequenced. In certain embodiments, synthetic Aβ binding peptides are designed and prepared, using portions of the anti-Aβ antibody sequences. The antibodies and peptides are of use for treatment of AF or for treatment of individuals at risk of developing AD. Compositions comprising anti-Aβ antibodies or Aβ binding peptides are also disclosed. | 2009-01-22 |
20090023628 | Cosmetic Composition and a Process for Preparing This Cosmetic Composition and a Cosmetic Product - The present invention relates to a cosmetic composition comprising: a wetting system that comprises at least glycerin in an amount ranging from 8.0% to 10% by weight, based on the total weight of the composition; an emollient system that comprises at least cetyl lactate and Shea butter; an emulsifying system that comprises at least steareth-2 and steareth-21; an oiliness adsorbing system that comprises at least nylon 12; and a silicone system that comprises at least cyclomethicone and cyclomethicone and dimethicone crosspolymer. This multifunctional cosmetic composition exhibits rapid absorption, properties of differentiated softness, smoothness and intensive and prolonged hydration when applied to the skin. Further, the present invention relates to a process of preparing the referred-to cosmetic composition and to a cosmetic product that comprises said composition. | 2009-01-22 |
20090023629 | COMPOSITIONS COMPRISING POLYCATION-COMPLEXED PROTEIN CRYSTALS AND METHODS OF TREATMENT USING THEM - The present invention relates to compositions comprising polycation-complexed protein crystals and hyaluronic acid. Advantageously, the compositions of this invention are stable, long-acting and avoid local reactions at the injection site. Compositions according to this invention include sustained-release human growth hormone compositions. Such compositions are useful for treating a subject having a disorder associated with human growth hormone deficiency or that is ameliorated by human growth hormone therapy. | 2009-01-22 |
20090023630 | Methods and Means for Use in Diagnostics and Treatment of Diabetes - The present invention identified novel epitopes from the insulin B chain which is embodied in methods and means for diagnostics and treatment of type 1 diabetes. The epitopes were found in a peptide comprising a fragment of the human insulin B chain. Using HLA-A2 tetramers having the peptide of the invention cytotoxic T-cells were found in peripheral blood cells samples from healthy individuals. The invention demonstrates that these autoreactive CTL directed against insulin B chain are able to destroy insulin producing beta-cells. Moreover, a significant proportion of cytotoxic T-cells from islet transplant recipients with recurrent autoimmunity and loss of insulin production recognized this peptide or analogue thereof. The peptide has a high affinity for the HLA-A2 allele, in particular HLA-A*0201. Based on the novel epitopes according to the invention, diagnostic and therapeutic methods and medicaments for the prevention or treatment of type 1 diabetes are provided. | 2009-01-22 |
20090023631 | Composition and Method of Use for Soft Tissue Augmentation/Drug Delivery - A composition for augmenting soft tissue and drug delivery is provided. The composition includes an active ingredient, a carrier, and a cross-linking agent, wherein the carrier is cross-linked with the cross-linking agent and the active ingredient is combined with the cross-linked carrier into a combination having a therapeutic effect. Techniques are also provided for producing a composition for augmenting soft tissue. Also, techniques are provided for soft tissue augmentation. Additionally, techniques are also provided for delivering a composition. | 2009-01-22 |
20090023632 | Hemoglobin-haptoglobin complexes - Construct-complexes of a hemoglobin, a hepatocyte modifying substance bound to the hemoglobin, and a haptoglobin bound to the hemoglobin, are provided, for administration to mammalian patients. The construct-complex may be formed ex vivo, or a hemoglobin-hepatocyte modifying substance combination may be administered to the patient so that haptoglobin in the mammalian body bonds thereto to form the construct-complex in vivo. Disorders of the liver may be diagnosed and treated using construct-complexes described herein. | 2009-01-22 |
20090023633 | REGULATION OF MINERAL AND SKELETAL METABOLISM - A method is disclosed whereby levels of calcium, phosphate and parathyroid hormone are measured in a patient. The patient is treated with a formulation comprising a compound having phosphotonin activity and thereafter measurements are made again. Dosing of the formulation is adjusted based on measurements with measuring, administering and adjusting dosing continually repeated as needed. | 2009-01-22 |
20090023634 | REGULATION OF MINERAL AND SKELETAL METABOLISM - A method is disclosed whereby levels of calcium, phosphate and parathyroid hormone are measured in a patient. The patient is treated with a formulation comprising a compound having phosphotonin activity and thereafter measurements are made again. Dosing of the formulation is adjusted based on measurements with measuring, administering and adjusting dosing continually repeated as needed. | 2009-01-22 |
20090023635 | Factor VII or VIIa - Like Molecules - Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided. | 2009-01-22 |
20090023636 | Methods and compositions for the prevention and treatment of anemia - Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs. | 2009-01-22 |
20090023637 | Methods for detecting and treating interstitial cystitis - The invention provides a method for diagnosing and inhibiting conditions associated with reduced amounts of THP and/or reduced amounts of total carbohydrate content in the THP, such as Interstitial Cystitis and its symptoms, and damaged mucin layers in a subject by administering an effective amount of a Tamm-Horsfall protein to the subject. The invention also provides a method for diagnosing Interstitial Cystitis in a subject by quantitatively determining in a sample, the level of THP, the amount of sialylation of Tamm-Horsfall protein and/or the total carbohydrate content in THP. A decrease in the amounts of THP, sialylation of Tamm-Horsfall protein and/or carbohydrate content in THP is indicative of Interstitial Cystitis. | 2009-01-22 |
20090023638 | SPILL RESISTANT ANTIBIOTIC FORMULATIONS - The disclosure is directed to a pharmaceutical kit with a first set, a second set and a third set of components. The first set of components can be a carbomer in an aqueous vehicle, the second set of components can be an antibiotic, and the third set of components can be a neutralizing agent. In exemplary embodiments, the first, second and third sets of components can be mixed together to form a spill resistant composition. | 2009-01-22 |
20090023639 | Methods of Treatment - A method of treating weight loss due to underlying disease in a patient, the method comprising administering to the patient an effective amount of an agent which reduces sympathetic nervous system activity. A method of treating weight loss due to underlying disease in a patient the method comprising administering to the patient an effective amount of any one or more of the following: a compound which inhibits the effect of aldosterone such as an aldosterone antagonist; a chymase inhibitor; a cathepsin B inhibitor; a β receptor blocker; an imidazoline receptor antagonist; a centrally acting α receptor antagonist; a peripherally acting α receptor antagonist; a ganglion blocking agent; a drug that has an effect on cardiovascular reflexes and thereby reduces SNS activity such as an opiate; scopolamine; an endothelin receptor antagonist; and a xanthine oxidase inhibitor. The methods are particularly useful in treating cardiac cachexia. | 2009-01-22 |
20090023640 | Use Of A Cyclic Undecapeptide For The Preparation Of A Medicament For Administration During Myocardial Ischaemic Events - The invention relates to the use of a cyclic undecapeptide, with the structure in formula (I), for the preparation of a medicament for administration during a myocardial ischaemic event. | 2009-01-22 |
20090023641 | Cyclic Antimicrobial Peptides - The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections. | 2009-01-22 |
20090023642 | Isolation, Purification, and Structure Elucidation of the Antiproliferative Compound Coibamide A - Novel antiproliferative compounds, compositions comprising the same, and methods of use thereof are disclosed. | 2009-01-22 |
20090023643 | Methods For Treating Acute Myocardial Infarction By Administering Calcitonin Gene Related Peptide And Compositions Containing The Same - This invention relates to methods of treating acute myocardial infarction by administering calcitonin gene related peptide (CGRP). This invention also relates to preventing an acute myocardial infarction by administering calcitonin gene related peptide (CGRP). This invention further relates to compositions of CGRP for use in such methods. This invention also relates to the use of calcitonin gene related peptide in the manufacture of medicament for treating or preventing an acute myocardial infarction in a subject or for treating a subject suspected of having an acute myocardial infarction. | 2009-01-22 |
20090023644 | Methods of using cgrp for cardiovascular and renal indications - The present invention provides methods of treating and preventing mortality associated with heart failure and renal insufficiency in a Stage B, C, or D heart failure patient, and for improving quality of life by providing improved methods of administering a therapeutically effective amount CGRP. One method comprise administering between about 50 and about 500 ng/min of CGRP for a time between 30 minutes and 8 hours per day for as many days as needed to provide symptomatic relief, prevent exacerbation of symptoms, and/or prevent and/or delay progression of the disease state of heart failure in said patient. The therapies can be administered on an outpatient or inpatient basis. | 2009-01-22 |
20090023645 | AIB1, a novel steroid receptor co-activator - The invention features a substantially pure DNA which includes a sequence encoding a novel steroid receptor co-activator which is overexpressed in breast cancer cells, diagnostic assays for steroid hormone-responsive cancers, and screening assays to identify compounds which inhibit an interaction of the co-activator with the steroid hormone. | 2009-01-22 |
20090023646 | GHRH analogues - The present invention relates to growth hormone-releasing hormone (GHRH) analogues. More particularly, the invention relates to synthetic GHRH analogues of amino acids or more, exhibiting concomitantly an increased resistance to proteolysis and high binding affinity to human GHRH receptor in in vitro studies, in comparison with human native GHRH (1-29)NH | 2009-01-22 |
20090023647 | METHOD OF PRODUCING BIOLOGICALLY ACTIVE HUMAN ACIDIC FIBROBLAST GROWTH FACTOR AND ITS USE IN PROMOTING ANGIOGENESIS - The present invention relates to the treatment of coronary heart disease by revascularization therapy, and more particularly to the intramyocardial injection of a pharmaceutical composition comprising a recombinant fibroblast growth factor-1 protein or a fragment of a recombinant fibroblast growth factor-1 protein, optionally, with a physiologic glue for inducing local neoangiogenesis in ischemic myocardium. Methods of producing the recombinant fibroblast growth factor 1 protein and fragments are also disclosed. | 2009-01-22 |
20090023648 | Methods for Treating Body Tissue - Methods of treating body tissue including repairing defects in body tissue as well as augmenting body tissue. Body tissue defects are repaired by injecting a polymeric adhesive composition through an injector into the region of the defect and allowing the adhesive composition to cure to repair the defect or to form an implant that adheres to at least one surface tissue in the region of the defect. Body tissue is augmented by filling a defect void with a polymeric adhesive composition and allowing it to cure. | 2009-01-22 |
20090023649 | Recombinant proteins containing shiga-like toxin and vascular endothelial growth factor fragments - The present invention is directed to an isolated polypeptide including: (1) the A subunit of Shiga-like bacterial toxin, wherein said subunit has the nucleic acid sequence of SEQ ID NO:9; and (2) human vascular endothelial growth factor wherein the growth factor has the nucleic acid sequence of SEQ ID NO:10; wherein the isolated polypeptide possesses ribosome inactivating activity. The present invention is also directed to compositions for inhibiting endothelial cell growth in a patient. | 2009-01-22 |
20090023650 | Treatment of egfr-dependent tumors by abin (a20 -binding inhibitor of nf kappab) - The present invention relates to the treatment of epidermal growth factor-family receptor- (ErbB-) dependent tumors. More specifically, the present invention relates to the use of ABIN for the preparation of a medicament to inhibit epidermal growth factor- (EGF-) induced proliferation, and to treat ErbB-dependent tumors. | 2009-01-22 |
20090023651 | INHIBITORS OF HUMAN PLASMIN DERIVED FROM THE KUNITZ DOMAINS - This invention provides: novel proteins, which are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and which are capable of inhibiting plasmin; uses of such novel proteins in therapeutic, diagnostic, and clinical methods; and polynucleotides that encode such novel proteins. | 2009-01-22 |
20090023652 | POLYCATIONIC CALCIUM MODULATOR PEPTIDES FOR THE TREATMENT OF HYPERPARATHYROIDISM AND HYPERCALCEMIC DISORDERS - The present invention provides methods and kits for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders. In particular, methods for lowering serum PTH and serum calcium using polycationic calcium modulator peptides are provided. The calcium modulator peptides can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis. | 2009-01-22 |
20090023653 | Method of using broad-spectrum delta-endotoxins - Disclosed are novel synthetically-modified | 2009-01-22 |
20090023654 | AXMI-008, A DELTA-ENDOTOXIN GENE AND METHODS FOR ITS USE - Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin and delta-endotoxin-associated polypeptides are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated delta-endotoxin and delta-endotoxin-associated nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequences shown in SEQ ID NOS:3, 5, and 7, and the nucleotide sequences set forth in SEQ ID NO:1, 2, 4, and 6, as well as variants and fragments thereof. | 2009-01-22 |
20090023655 | Biased Ligands for Receptors Such as the PTH Receptor - Disclosed are compositions and methods for modulating the β-arrestin pathway selectively over the G protein pathway of a G protein couple receptor, such as parathyroid hormone receptor. | 2009-01-22 |
20090023656 | Combination Comprising Combretastatin and Anticancer Agents - This invention relates to therapeutic combinations comprising VEGF Trap and a stilbene derivative, and to methods for treatment of cancer comprising administration of such combinations. | 2009-01-22 |
20090023657 | CATECHOLAMINE REGULATED PROTEIN - A novel family of mammalian catecholamine proteins is identified. These proteins are useful in methods of diagnosing neurological diseases, including schizophrenia and bipolar disease, as well as cardiovascular disease. This family of CRP40 proteins are also useful to treat neurological diseases. | 2009-01-22 |
20090023658 | Neovascularization Inhibitors Derived From HGF and Methods Involving the Same - Novel neovascularization inhibitory factors and neovascularization inhibitors useful in preventing and treating various diseases in association with neovascularization. These neovascularization inhibitors contain as the active ingredient polypeptides with the following definition (a) or (b): (a) a polypeptide having an amino acid sequence of PyrGlu | 2009-01-22 |
20090023659 | Methods and Materials Relating to CD84-like Polypeptides and Polynucelotides - The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human spleen (Hyseq clone identification numbers 2938352 (SEQ ID NO: 1)). Other aspects of the invention include vectors containing processes for producing novel human secreted CD84-like polypeptides, and antibodies specific for such polypeptides. | 2009-01-22 |
20090023660 | Novel Hemopoietin Receptor Protein, NR12 - A novel hemopoietin receptor gene (NR12) was successfully isolated by extracting motifs conserved among the amino acid sequences of known hemopoietin receptors and by using the predicted sequence. The NR12 gene encodes two forms of proteins, a transmembrane type and a soluble type. The expression of the NR12 gene was detected in tissues containing hematopoietic cells. NR12 is a novel hemopoietin receptor molecule involved in the regulation of immune system and hematopoiesis in vivo. Thus, NR12 is useful in the search for novel hematopoietic factors that functionally bind to the NR12 receptor, and in the development of therapeutic drugs for diseases associated with immunity or hematopoiesis. | 2009-01-22 |
20090023661 | Use of Antagonists of the Bradykinin B2 Receptor for the Treatment of Osteoarthrosis - Peptides having bradykinin-antagonistic action are suitable for the production of pharmaceuticals for the prophylaxis and therapy of diseases in whose course an increased activity of matrix metalloproteinases is involved. These include diseases such as degenerative joint diseases, for example osteoarthrosis, spondylosis and chondroporosis after joint trauma or relatively long immobilization of a joint after meniscus or patella injuries or torn ligaments. The invention therefore relates to the use of a compound of the formula I, | 2009-01-22 |
20090023662 | Identification of Agonistic Autoantibodies Associated with Humoral Kidney Rejection - The invention relates to a method for detecting autoantibodies associated with humoral kidney rejection, which recognize extracellular structures of G protein-coupled receptors, and to the use of peptides, which comprise these loops or fragments thereof, for treating humoral kidney rejection. | 2009-01-22 |
20090023663 | Thymosin beta 4 compositions and methods - A method of treatment for skin, dermal or epidermal tissue utilizes a composition including an actin-binding polypeptide which may include amino acid sequence LKKTET [SEQ ID NO: 1] or a conservative variant thereof. | 2009-01-22 |
20090023664 | ALPHA- AND BETA-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS - α- and β-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. | 2009-01-22 |
20090023665 | ANTIBIOTICS GE 81112 FACTORS A, B, B1, PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS, AND USE THEREOF - The invention relates to an antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 81112 factor A, factor B1 and factor B, which is produced by fermentation of | 2009-01-22 |
20090023666 | Modulators of Hypoxia Inducible Factor-1 and Related Uses - The invention features compounds of formulas I or II: and pharmaceutically acceptable salts and prodrugs thereof, as well methods for modulating the effects of local and systemic hypoxic events using the compounds. | 2009-01-22 |
20090023667 | Composition For Preventing Harmful Organisms - An object of the present invention is to provide a composition for preventing harmful organisms exerting an excellent control effect against plant diseases and/or insecticidal effect. Disclosed is a composition for preventing harmful organisms comprising a diamine derivative represented by the formula (1), and one or more compounds selected from the group consisting of other fungicides, insecticides and acaricides as active ingredients, | 2009-01-22 |
20090023668 | Method for treating blepharitis - The present invention is related to a method for treating blepharitis, the method comprising administering to an ocular area of a subject in need thereof a composition comprising about 0.001% to about 0.01% (w/v) dexamethasone and an antibiotic, wherein the composition is substantially free of lipids, and wherein the composition is ophthalmically acceptable. | 2009-01-22 |
20090023669 | Antibacterial Agents - The present invention, in one aspect, provides a method of inhibiting bacterial growth by contacting bacteria with an effective amount of at least one monosaccharide compound of formula (1) as described herein: | 2009-01-22 |
20090023670 | Regulation of Transgene Expression by RNA Interference - Expression of transgenes delivered into a host organism cells can be regulated by RNA effector molecules delivered to or present in the host organism cells. Regulation can be mediated by delivery of RNA interference inducing molecules that target the transgene mRNA or by incorporating engineered RNA effector binding sites into the transgene. Temporary or long term regulation of expression can be achieved depending on the nature and dosing of RNA effector. | 2009-01-22 |
20090023671 | Rnai Agents for Maintenance of Stem Cells - The present invention provides compositions and methods suitable for delivering RNAi agents against genetic targets in stem cells so as to direct cell growth and differentiation. | 2009-01-22 |
20090023672 | AGE-2 APTAMER - An AGE-2 aptamer which binds to a glyceraldehyde-derived advanced glycation end product (AGE-2) but not to human serum albumin and comprises at least 35 bases and in which the cytosine content in the bases is at least 35%, or the guanine content in the bases is at least 32%. Since the AGE-2 aptamer can be used for detecting AGE-2, it can be used as a reagent for detection/diagnosis, and an agent for prevention/treatment of AGE-2 involved diseases such as: diabetic complications such as diabetic retinopathy, diabetic nephropathy, and diabetic neuropathy; neurodegenerative diseases such as Alzheimer's disease; and proliferation, metastasis, and invasion of malignant tumors. | 2009-01-22 |
20090023673 | LIPID CONTAINING FORMULATIONS - Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described. | 2009-01-22 |
20090023674 | snRNA gene-like transcriptional units and uses thereof - By a computer search for upstream promoter elements (DSE, PSE) typical of small nuclear RNA (snRNA) genes, we have identified a number of previously unrecognized, putative transcription units whose predicted products are novel noncoding RNAs with homology to protein-coding genes. By elucidating the function of one of them, we provide evidence for the existence of a sense/antisense-based gene regulation network where part of the Pol III transcriptome could control its Pol II counterpart. | 2009-01-22 |
20090023675 | RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA) - The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism. | 2009-01-22 |
20090023676 | RNA Interference Mediated Inhibition of MAP Kinase Gene Expression or Expression of Genes Involved in MAP Kinase Pathway Using Short Interfering Nucleic Acid (SiNA) - The present invention concerns methods and reagents useful in modulating MAP kinase gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against c-JUN, JNK, p38, and ERK gene expression, useful in the treatment of cancer, inflammation, obesity and insulin resistance (e.g. Type I and Type II diabetes). | 2009-01-22 |
20090023677 | Modulation of Telomere Length in Telomerase Positive Cells and Cancer Therapy - Induction of telomere shortening, G2 arrest and apoptosis in telomerase positive cancer cells using acyclic nucleoside analogs has been disclosed. In addition, methods for impairment or prevention of tumorigenic telomerase positive cells from having a chance to grow into a tumor and methods for promoting tumor regression (decrease in size of an established tumor) using acyclic nucleoside analogs has been disclosed. | 2009-01-22 |
20090023678 | Amino Acid Vitamin Ester Compositions for Controlled Delivery of Pharmaceutically Active Compounds - The invention relates to pharmaceutical compositions that provide sustained-release of a pharmaceutically active compound and to methods of treating or preventing a condition in an animal by administering the pharmaceutical compositions to the animal. When the pharmaceutical compositions are administered to an animal by injection, they form a drug depot that releases the pharmaceutically active compound over time. The pharmaceutical compositions can also be administered orally. | 2009-01-22 |
20090023679 | Compounds and methods for treatment of sickle cell disease or complications associated therewith - Compounds, compositions and methods are provided for treatment of sickle cell disease or a complication associated therewith, or graft versus host disease, in an individual. More specifically, the use of particular glycomimetics for the treatment is described. | 2009-01-22 |
20090023680 | Fixed ratio drug combination treatments for solid tumors - Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine. Such methods are particularly useful in the treatment of cancer patients with advanced solid tumors. | 2009-01-22 |
20090023681 | METHOD OF USING BETA-GLUCAN FROM SCHIZOPHYLLUM COMMUNE - Disclosed herein is a method for high-yield production of | 2009-01-22 |
20090023682 | Composition Comprising Dietary Fat Complexer and Methods of Using Same - A composition includes α-cyclodextrin and at least one lipase inhibitor. A method for promoting weight loss, inhibiting weight gain, or maintaining weight in a subject in need thereof includes administering α-cyclodextrin and at least one lipase inhibitor to the subject, thereby reducing the bioavailability of ingested fat and reducing the unpleasant gastrointestinal side effects. | 2009-01-22 |
20090023683 | COMPLEXES COMPRISING ZOLEDRONIC ACID AND CYCLODEXTRINS - The present invention relates to stable compositions comprising zoledronic acid, wherein zoledronic acid is complexed with a cyclodextrin, such as hydroxypropyl-β-cyclodextrin. The invention further relates to processes for making the compositions. | 2009-01-22 |
20090023684 | FLUID FOR PERITONEAL DIALYSIS - The present invention has an object to provide a fluid for peritoneal dialysis with satisfactory body fluid removability, high biocompatibility, and improved storage stability, and the object is attained by a fluid for peritoneal dialysis containing one or more saccharides selected from cyclonigerosylnigerose, cyclomaltosylmaltose, and L-ascorbic acid 2-glucoside. | 2009-01-22 |
20090023685 | Nebulized or Sprayed Cidofovir for Recurrent Respiratory Papillomatosis - A solution of 2.5-20% cidofovir is administered as droplets having a mean size of about 1 micron to about 20 microns either nebulized or as a spray to an individual having recurrent respiratory papillomatosis. | 2009-01-22 |
20090023686 | METHODS FOR THE PREPARATION AND USE OF FERRIC PYROPHOSPHATE CITRATE CHELATE COMPOSITIONS - A highly water soluble ferric pyrophosphate citrate chelate useful for treating iron deficiency contains 2% or less phosphate by weight. These chelate compositions are easily milled and/or processed into dosage forms using conventional techniques, and are expected to exhibit advantageous biocompatibility as compared to conventional soluble ferric pyrophosphates, ferric salts, ferric polysaccharide complexes and ferrous salts. | 2009-01-22 |
20090023687 | Method for Controlling Phytopathogenic Organisms - The present invention is directed to methods of protecting crops of useful plants against attack by phytopathogenic organisms as well as the treatment of crops of useful plants infested by phytopathogenic organisms comprising administering a combination of glyphosate and at least one fungicide to the plant or locus thereof. | 2009-01-22 |
20090023688 | Microbicidal composition - Synergistic microbicidal compositions containing N-methyl-1,2-benzisothiazolin-3-one. | 2009-01-22 |
20090023689 | Oral drug delivery system - Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds. | 2009-01-22 |
20090023690 | Oral drug delivery system - Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds. | 2009-01-22 |
20090023691 | DELAYING THE AGEING PROCESS AND DISORDERS CAUSED BY AGEING - The present invention relates to the field of ageing, particularly to the prevention and/or treatment of ageing process and disorders caused by ageing and particularly to the prevention and/or treatment of atherosclerosis, neurodegenerative disorders and malignant diseases. A composition is provided, which comprises four or more active ingredients to reduce or suppress the ageing process or symptoms associated therewith. | 2009-01-22 |
20090023692 | COMPOSITIONS FOR INHIBITING AND PREVENTING VASCULAR OCCLUSION CONTAINING NUTRITIONAL SUPPLEMENTS - Compositions for inhibiting vascular occlusion in humans comprising aspirin for inhibiting vascular occlusion which further contain nutritional supplements are disclosed. The compositions are provide in a dosage form that provides stability of the active ingredient allowing for improved shelf life. A further composition included a cholesterol-lowering agent in combination with aspirin and optionally with nutritional supplements. | 2009-01-22 |
20090023693 | NEW DROSPIRENONE/17BETA-ESTRADIOL REGIMEN, PHARMACEUTICAL COMBINATION PRODUCT AND KIT FOR PERFORMING THIS REGIMEN - The present invention relates to a pharmaceutical combination product with at least 21 daily consecutive dosage units containing from 2.0 mg to 3.0 mg of drospirenone and 1.0 to 2.0 mg of 17β-estradiol in each daily dosage unit followed by intermittent daily dosage units containing the same or smaller amount of drospirenone (i.e. 0.5 mg to 3.0 mg) as the consecutive daily dosage units wherein each intermittent daily dosage unit is preceded by at least one day without administration of drospirenone. | 2009-01-22 |
20090023694 | Contraceptive - The present invention relates to an administration form for hormonal contraception consisting of a particular number of hormone-containing daily units, comprising a hormone combination consisting of at least one oestrogen selected from the group comprising ethinyl oestradiol (I) and oestradiol (II) as the oestrogen component, and at least one metabolite of chlormadinone acetate selected from the group comprising 3α-hydroxy-6-chloro-17α-acetoxy-4,6-pregnadien-20-one (3α-hydroxy-chlormadinone acetate), 3β-hydroxy-6-chloro-17α-acetoxy-4,6-pregnadien-2-one (3β-hydroxy-chlormadinone acetate), optionally mixed with chlormadinone acetate and/or 3α-hydroxy-17α-acetoxy-5β-pregnan-20-one and/or 3β-hydroxy-17α-acetoxy-5β-pregnan-20-one as the gestagen component for the uninterrupted, daily, oral administration of the hormone-containing daily units, optionally in combination with 7 to 3 hormone-free daily units. | 2009-01-22 |
20090023695 | METHOD OF MAKING AND USING 7alpha,11beta-DIMETHYL-17beta-HYDROXYESTR-4-EN-3-ONE 17-UNDECANOATE - Methods of using 7α,11β-dimethyl-17β-hydroxy-4-estren-3-one bucyclate (I) and 7α,11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate (II) | 2009-01-22 |
20090023696 | USE OF C3-C10 17ALFA-ESTERS OF 9,11-DEHYDROCORTEXOLONE AS ANTI-GONADOTROPHIC AGENTS - The present invention relates to the use of C | 2009-01-22 |
20090023698 | METHODS OF MANUFACTURING BIOACTIVE 3-ESTERS OF BETULINIC ALDEHYDE AND BETULINIC ACID - The present invention provides a method for preparing a compound of formula (I), the method comprising contacting a compound of formula (II) with an effective amount of a compound of formula (III) or (IV). The present invention also provides a method for preparing a compound of formula (VI), the method comprising contacting a compound of formula (II) with an effective amount of one or more of 2,2-dimethylsuccinic acid, 2,2 dimethylbutanedioyl dichloride, 2,2-dimethylbutanedioyl dibromide, and 2,2 dimethylsuccinic anhydride. The present invention also provides a compound obtained from the method of the present invention. | 2009-01-22 |
20090023699 | Method For Obtaining a Natural Mixture of Conjugated Equine Estrogens Depleted in Non-Conjugated Lipophilic Compounds - A method for obtaining an extract containing the natural mixture of conjugated equine estrogens by liquid-liquid extraction of the mixture of conjugated equine estrogens, wherein the mixture obtained is depleted in non-conjugated lipophilic compounds selected from the group consisting of non-conjugated flavonoids, non-conjugated isoflavonoids, non-conjugated norisoprenoids, non-conjugated steroids, in particular androstane and pregnane steroids, and comparable non-conjugated compounds. | 2009-01-22 |
20090023700 | NEUROPROTECTIVE TREATMENTS - The present invention provides a therapeutic method for treating traumatic neural injury or a degenerative disorder in a mammal by administering a neuroprotective compound, wherein the neuroprotective compound is a peroxovanadium compound, a peroxovandium derivative, or a compound with inhibitory activity of protein tyrosine phosphatases. | 2009-01-22 |
20090023701 | Cytokine Inhibitors - Disclosed are compounds of formula (I) | 2009-01-22 |
20090023702 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS - Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR 119 G protein-coupled receptor modulator therapy. These novel compounds have the structure Formula I or Formula IA. | 2009-01-22 |
20090023703 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase - Compounds represented by Formula (I): | 2009-01-22 |
20090023704 | Novel Compounds 737 - The present invention relates to novel xanthine compounds of the general formula (I) | 2009-01-22 |
20090023705 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF MOOD DISORDERS, SLEEP DISORDERS OR ATTENTION DEFICIT DISORDERS - The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a compound selected from the group consisting of DOPA decarboxylase inhibiting compounds, catechol-O-methyltransferase inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiting compounds, selective serotonin reuptake inhibiting compounds, tricyclic antidepressant compounds, serotonin norepinephrine reuptake inhibiting compounds, norepinephrine dopamine reuptake inhibiting compound, noradrenergic and specific serotonergic antidepressants, and combinations thereof. The inventive compositions are particularly useful in the treatment of depression, narcolepsy, insomnia, and Attention Deficit/Hyperactivity Disorder (AD/HD). | 2009-01-22 |
20090023706 | Method of Treating Organophosphorous Poisoning - The present invention is directed to various methods for treating organophosphorus poisoning in an animal that is at risk of exposure to an organophosphorus compound or preventing organophosphorus poisoning in an animal that has been exposed to an organophosphorus compound, by administering a therapeutically effective amount of galantamine or a salt thereof, or a biologically active analog, derivative, fragment or variant thereof. | 2009-01-22 |
20090023707 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS - The present invention provides a compound of formula I: | 2009-01-22 |
20090023708 | Compounds Comprising a Lactam or a Lactam Derivative Moiety, Processes for Making Them, and Their Uses - The present invention relates to compounds of formula (I) comprising a lactam or a lactam derivative moiety, processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as pharmaceuticals. | 2009-01-22 |
20090023709 | Inhibitors of 11B-Hyrdoxysteroid Dehydrogenase - Provided herein are compounds of the formula (I): | 2009-01-22 |
20090023710 | Compound - There is provided a compound having Formula (I) wherein each of R | 2009-01-22 |
20090023711 | Piperazines and Piperidines as Mglur5 Potentiators - Compounds of Formula I or pharmaceutically acceptable salts or solvates thereof: | 2009-01-22 |
20090023712 | Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin - The invention relates to new pharmaceutical compositions for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment ADHD and methods for the preparation thereof. | 2009-01-22 |
20090023713 | HETEROCYCLIC COMPOUNDS - The invention is concerned with novel heterocyclyl compounds of formula (I) | 2009-01-22 |
20090023714 | COMBINED PREPARATION OF A THIAZIDE DIURETIC AND A LOOP DIURETIC - The invention relates to pharmaceutical preparations which contain a combination of a thiazide diuretic and a low-dose loop diuretic and which are particularly useful for treating hypertension and heart failure. It is not only the overall natriuretic/diuretic effects which are increased due to said combination of thiazide diuretic and loop diuretic, but the undesired secondary effects regarding potassium and magnesium losses are significantly reduced as well. As a result, the desired hypocalciuric effect of the thiazide is maintained despite the presence of the loop diuretic. | 2009-01-22 |
20090023715 | Wound Healing - A phenothiazinium compound, compositions and medicaments for use in promoting wound healing and a method for promoting wound healing or cosmetic use by applying or administering a phenothiazinium compound to a wound site or the skin, and optionally exposing the wound site or skin to light. | 2009-01-22 |
20090023716 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents - The present invention relates to a compound, useful as a mineralocorticoid receptor-modulating agent, of the following formula [I]: | 2009-01-22 |
20090023717 | MORPHINE-BRIDGED INDAZOLE DERIVATIVES - The present invention relates to novel morpholine-bridged indazole derivatives which stimulate soluble guanylate cyclase, to process for the preparation thereof, and to the use thereof for producing medicaments, in particular medicaments for the treatment of disorders of the central nervous system. | 2009-01-22 |
20090023718 | Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives - The present invention relates to a novel class of hydroxamic acid derivatives having a diamine or iminodiacetic acid backbone. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively including terminal differentiation, arresting cell growth and/or apoptosis of neo-plastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compound of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives, and safe, dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo. | 2009-01-22 |